PCM
CATX icon

Polymer Capital Management’s Perspective Therapeutics CATX Stock Holding History

Polymer Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,083
Closed -$54.6K – 672
2026
Q1 		$54.6K Buy
+13,083
New +$55.3K 0.01% 799

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Polymer Capital Management's CATX Position: Q2 2026 in Review

Polymer Capital Management sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 13,083 shares — an estimated $54.6K sold.

Polymer Capital Management first reported a position in CATX in Q1 2026 and held it in 1 quarter. The position peaked at $54.6K in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Polymer Capital Management reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Polymer Capital Management sold 13,083 Perspective Therapeutics shares in Q2 2026, an estimated $54.6K.
  • Polymer Capital Management first reported a position in Perspective Therapeutics in Q1 2026 and held it in 1 quarter.
  • Polymer Capital Management's Perspective Therapeutics position peaked at $54.6K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Polymer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.